MedTrace Logo

Management and Outcome of Scorpion Sting in Children

NCT06615440 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-09-26

No results posted yet for this study

Summary

To determine the clinical characteristics of children with scorpion sting and implement guidelines for management of those children and observe the outcome

Conditions

  • Scorpion Stings

Interventions

DRUG

Alpha blocker

prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
0 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2026-09-30
Completion
2026-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06615440 on ClinicalTrials.gov